Qatar Pharmaceuticals and Healthcare Report Q1 2013
Business Monitor International, January 2013, Pages: 83
BMI View
According to recent reports in The Gulf Times, Qatar will have four new drug manufacturers by the end of Q113. The drugmakers will reportedly import their raw materials and produce tablets,
syrups and injectables. It is anticipated the drug manufacturers will (in our view eventually) help curb reliance on imports and lower prices of retail medicines in the country as a result of increased local competition, according to Dr Aisha al-Ansari of the Supreme Council of Health Pharmacy and Drug Control Department (SCH). If the production facilities are opened on schedule, we will revise our forecasts accordingly. Generally speaking, however, we expect Qatar to remain greatly reliant on imported medicines, given the high level of consumption of patented drugs.
Headline Expenditure Projections
- Pharmaceuticals: QAR1.32bn (US$362mn) in 2011 to QAR1.38bn (US$379mn) in 2012;
+4.7% in local currency and US dollar terms. Historical figures adjusted to reflect new import data.
- Healthcare: QAR10.54bn (US$2.89bn) in 2011 to QAR11.40bn (US$3.13bn) in 2012; +8.2
%in local currency and US dollar terms. Forecast slightly lower from Q412 on account of macroeconomic factors.
- Medical devices: QAR1.02mn (US$279mn) in 2011 to QAR1.15mn (US$317mn) in 2012;
+13.6% in local currency and US dollar terms. Forecast slightly lower from Q412 on account of macroeconomic factors.
Risk/Reward Rating
In BMI's Q113 Risk/Reward Ratings (RRRs) for the Middle East and Africa
(MEA) region, Qatar remains in fourth place, out of the 30 countries assessed. Its composite score - at an unchanged 56.2 - comprises a more favourable risk component. The country's longer-term rewards are weighed down by factors such as its small population and a maturing pharmaceutical market.
Key Trends And Developments
- A report has found that Qatar and Saudi Arabia lead in the healthcare interiors contracting and fit-out sector, with investments of US$192mn and US$145mn respectively in 2012. The report by Ventures ME showed that the two countries have surpassed investments of US$119mn and US$13mn in the sector by the UAE and Oman respectively. The report also found that projects worth US$2.4bn in the Qatari healthcare market are likely to be completed by end-2012, thereby making the country the largest spender on healthcare in the GCC. This represents a share of 40
%of the total GCC medical projects expected to be completed in 2012.
BMI Economic View
Qatar faces few significant fiscal risks in the near term, even though we see income from oil and gas exports as likely to be more than capable of financing Doha's spending plans over the coming years. However, we view the authorities' goal of fully financing its budget from nonhydrocarbon revenues by 2020 as unrealistic, and expect the country to remain dependent on oil and gas income for the foreseeable future.
BMI Political View
Qatar's Emir Sheikh Hamad bin Khalifa al-Thani recently called for Palestinian unity during a landmark visit to Gaza. The visit is the first by a head of the state since Hamas militants seized the territory five years ago. The Emir urged the Hamas and rival Palestinian group Fatah to reconcile. He also pledged US$400mn for building projects in the Gaza Strip. The visit shows that Gaza is not alone, according to Hamas Prime Minister Ismail Haniya, adding that Israel's economic and political blockade of Gaza had been broken by the trip.
Executive Summary 5
SWOT Analysis 7
Qatar Pharmaceuticals And Healthcare Industry SWOT 7
Qatar Political SWOT 8
Qatar Economic SWOT 8
Qatar Business Environment SWOT 9
Pharmaceutical Risk/Reward Ratings 10
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q113 11
Rewards 12
Risks 12
Qatar - Market Summary 14
Regulatory Regime 15
Regional Regulatory Developments 16
FTA Agreements 17
Intellectual Property Regime 18
Pricing And Reimbursement Regime 19
Drug Price Reform Failure 19
Industry Developments 21
Epidemiology 21
Non-Communicable Diseases 22
Communicable Diseases 25
Healthcare Sector 25
Regional Healthcare Sector Developments 27
Healthcare Reform 28
Health Insurance 29
Healthcare IT 30
Research & Development 31
Clinical Trials 33
Medical Devices Industry 33
Recent Developments in the Medical Devices Industry 34
Industry Forecast Scenario 36
Pharmaceutical Market Forecast 36
Table: Pharmaceutical Sales Indicators 2008-2016 38
Healthcare Market Forecast 39
Table: Healthcare Expenditure Indicators 2008-2016 40
Table: Government Healthcare Indicators 2008-2016 40
Table: Private Healthcare Indicators 2008-2016 41
Key Growth Factors - Macroeconomic 42
Prescription Drug Market Forecast 47
Table: Prescription Drug Sales Indicators 2008-2016 48
Patented Drug Market Forecast 49
Table: Patented Drug Market Indicators 2008-2016 50
Generic Drug Market Forecast 51
Table: Generic Drug Sales Indicators 2008-2016 52
OTC Medicine Market Forecast 53
Table: OTC Medicine Sales Indicators 2008-2016 54
Pharmaceutical Trade Forecast 55
Table: Exports and Imports Indicators, 2008-2016 56
Medical Device Market Forecast 57
Table: Medical Devices Sales Indicators 2008-2016 58
Other Healthcare Data 59
Table: Healthcare Professionals (2009) 60
Key Risks To BMI's Forecasts 61
Competitive Landscape 62
Pharmaceutical Industry 62
Pharmacy Wholesale And Retail 63
Company Profiles 64
Local Companies 64
Qatari German Company For Medical Devices (QGMD) 64
Medicare Group 66
Ebn Sina Medical 67
Qatar Pharma 68
Multinational Companies 69
Novartis 69
Merck & Co 70
GlaxoSmithKline 71
Pfizer 72
Demographic Outlook 73
Table: Population By Age Group, 1990-2020 ('000) 74
Table: Population By Age Group, 1990-2020 (% of total) 74
Table: Key Population Ratios, 1990-2020 75
Table: Rural And Urban Population, 1990-2020 76
Glossary 77
BMI Methodology 79
How We Generate Our Pharmaceutical Industry Forecasts 79
Pharmaceutical Risk/Reward Ratings Methodology 80
Ratings Overview 80
Table: Pharmaceutical Risk/Reward Indicators 81
Weighting 82
Table: Weighting Of Components 82
Sources 82
Company Profiles
Local Companies
Qatari German Company For Medical Devices (QGMD)
Medicare Group
Ebn Sina Medical
Qatar Pharma
Multinational Companies
Novartis
Merck & Co
GlaxoSmithKline
Pfizer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
